NCT01097070View on ClinicalTrials.gov

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
HIV-1 Infection
Interventions
DRUG

Bevirimat

Trial Locations (4)

30308

AIDS Research Consortium of Atlanta, Atlanta

33316

Gary J. Richmond, MD, PA, Fort Lauderdale

94115

Quest Clinical Research, San Francisco

02215

Community Research Initiative of New England, Boston

Sponsors

Lead Sponsor

Myrexis Inc.
All Listed Sponsors
lead

Myrexis Inc.

INDUSTRY

NCT01097070 - A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days | Biotech Hunter | Biotech Hunter